Velasco-Velázquez’s study found that the CCL5-CCR5 axis is highly activated in TNBC− and human epidermal growth factor receptor-2 (HER2)-positive breast cancers and that CCR5+ cells respond to CCL5. The gene discussed is CCR5; the disease is breast cancer.